CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


SARS-CoV-2 viral compositionWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug810 T-cell receptor (TCR) repertoire Wiki 1.00
drug909 Whole Genome Analysis Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018450 Disease Progression NIH 0.38

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 NGS Diagnostic in COVID-19 Hosts - Genetic Cause Relating to the Course of Disease Progression

In this study (i) the host genome to identify susceptibility regions of infection, inflammation, and host defense, (ii) host response to Severe Acute Respiratory Syndrome-Corona-Virus-2 (SARS-CoV-2) infection, and (iii) viral sequence composition to define viral sequences which may be correlated with disease severity in addition to the metagenome of the throat swab will be analysed .

NCT04364828 COVID-19 Genetic: Whole Genome Analysis Genetic: T-cell receptor (TCR) repertoire Genetic: SARS-CoV-2 viral composition
MeSH:Disease Progression

Primary Outcomes

Description: The change in the genetic makeup of a virus population (measured in numbers) as the viruses mutate and multiply over time at different time points

Measure: Viral evolution

Time: Day 1, Day 3-5, Day 7-9, 48 hours after recovery

Secondary Outcomes

Description: CD4+ and CD8+ T cells from blood (per µl) at different time points measured

Measure: Immune response

Time: Day 1, Day 3-5, Day 7-9, 48 hours after recovery

Description: Clinical classification according to severity: Light and uncomplicated (mild symptoms) Moderate (mild pneumonia) Severe pneumonia Critical (Acute Respiratory Distress Syndrome (ARDS), sepsis, septic shock) Evaluated at several time points

Measure: Disease severity

Time: Day 1, Day 3-5, Day 7-9, 48 hours after recovery


No related HPO nodes (Using clinical trials)